State Street’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-171,225
| Closed | -$141K | – | 4296 |
|
|
2025
Q1 | $141K | Hold |
171,225
| – | – | ﹤0.01% | 3897 |
|
|
2024
Q4 | $163K | Hold |
171,225
| – | – | ﹤0.01% | 3895 |
|
|
2024
Q3 | $171K | Sell |
171,225
-4,076
| -2% | -$4.51K | ﹤0.01% | 3856 |
|
|
2024
Q2 | $217K | Sell |
175,301
-3,000
| -2% | -$3.06K | ﹤0.01% | 3796 |
|
|
2024
Q1 | $232K | Hold |
178,301
| – | – | ﹤0.01% | 3841 |
|
|
2023
Q4 | $223K | Hold |
178,301
| – | – | ﹤0.01% | 3876 |
|
|
2023
Q3 | $232K | Hold |
178,301
| – | – | ﹤0.01% | 3897 |
|
|
2023
Q2 | $307K | Sell |
178,301
-601,102
| -77% | -$954K | ﹤0.01% | 3866 |
|
|
2023
Q1 | $1.14M | Buy |
779,403
+48,391
| +7% | +$92.8K | ﹤0.01% | 3491 |
|
|
2022
Q4 | $1.18M | Sell |
731,012
-4,087
| -0.6% | -$9.41K | ﹤0.01% | 3523 |
|
|
2022
Q3 | $2.46M | Buy |
735,099
+15,570
| +2% | +$70.3K | ﹤0.01% | 3359 |
|
|
2022
Q2 | $2.62M | Sell |
719,529
-1,206,870
| -63% | -$5.47M | ﹤0.01% | 3387 |
|
|
2022
Q1 | $13.9M | Buy |
1,926,399
+450,780
| +31% | +$3.84M | ﹤0.01% | 2640 |
|
|
2021
Q4 | $20.1M | Buy |
1,475,619
+823,589
| +126% | +$12.9M | ﹤0.01% | 2477 |
|
|
2021
Q3 | $13.7M | Buy |
652,030
+108,986
| +20% | +$2.34M | ﹤0.01% | 2700 |
|
|
2021
Q2 | $13M | Buy |
543,044
+318,839
| +142% | +$8.07M | ﹤0.01% | 2766 |
|
|
2021
Q1 | $6.56M | Sell |
224,205
-400
| -0.2% | -$11.7K | ﹤0.01% | 2937 |
|
|
2020
Q4 | $6.71M | Buy |
+224,605
| New | +$7.05M | ﹤0.01% | 2818 |
|
State Street's KRON Position: Q2 2025 in Review
State Street sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 171,225 shares — an estimated $141K sold.
State Street first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $20.1M in Q4 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- State Street reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- State Street sold 171,225 Kronos Bio shares in Q2 2025, an estimated $141K.
- State Street first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- State Street's Kronos Bio position peaked at $20.1M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on State Street's 13F filing for Q2 2025, filed 14 Aug 2025.